Compare · CI vs ILMN
CI vs ILMN
Side-by-side comparison of The Cigna Group (CI) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $74.45B, about 2.6x ILMN ($28.24B).
- Over the past year, CI is down 4.8% and ILMN is up 94.2% - ILMN leads by 99.0 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 10 for CI).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Illumina Inc.
- Price
- $281.46-0.49%
- $186.76-1.85%
- Market cap
- $74.45B
- $28.24B
- 1M return
- -3.62%
- +13.80%
- 1Y return
- -4.78%
- +94.24%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 10
- 11
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest CI
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities
- SEC Form 11-K filed by The Cigna Group
- The Cigna Group Foundation Invests $3 Million to Strengthen Youth Mental Health Through Nonprofits Across 10 States
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits